Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Global Forecasts to 2017
The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and is expected to reach $43.3 billion by 2017 at a CAGR of 14.0% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The global injectable drug delivery formulations technologies market was the largest segment in this market. This is due to surge of biologics and development of nanotechnologies. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
The growth of the injectable drug delivery technologies market is primarily triggered by product life cycle management, technological advancements, surge of biologics in pharmaceutical markets, rising incidences of cancer and diabetes at global level and improving patient compliance. The evolving opportunities in this market for manufacturers include development of biosimilars in pharmaceutical markets and focus of pharmaceutical manufacturers towards emerging markets such as, India, and China. However, factors such as needle-stick injuries and infections, development of alternate delivery methods and product recalls are restraining the growth of the market.
North America accounted for the largest market share of 41.3% of the global injectable drug delivery technologies market, followed by Europe (30.2%) in 2012. However, the region lags behind Europe in the self injection devices market. This is owing to low penetration rate of pen injectors in the U.S. Asian and Latin American countries represent the fastest growing markets due to growing number of cancer and diabetes incidences, and improving patent compliance. Furthermore, stringent regulatory policies for approval of medical devices, and high competition in mature countries will compel the companies to focus on the emerging markets in Latin America and Asia.
Scope of the Report
This research report categorizes the global injectable drug delivery technologies marketinto two segments, namely, global injectable drug delivery devices technologies and global injectable drug delivery formulations technologies. These markets are broken down into segments and sub-segments, providing value analysis for 2010, 2011, and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World) to provide in-depth information on the global scenario.
Global Injectable Drug Delivery Technologies Market, By Segment
The growth of the injectable drug delivery technologies market is primarily triggered by product life cycle management, technological advancements, surge of biologics in pharmaceutical markets, rising incidences of cancer and diabetes at global level and improving patient compliance. The evolving opportunities in this market for manufacturers include development of biosimilars in pharmaceutical markets and focus of pharmaceutical manufacturers towards emerging markets such as, India, and China. However, factors such as needle-stick injuries and infections, development of alternate delivery methods and product recalls are restraining the growth of the market.
North America accounted for the largest market share of 41.3% of the global injectable drug delivery technologies market, followed by Europe (30.2%) in 2012. However, the region lags behind Europe in the self injection devices market. This is owing to low penetration rate of pen injectors in the U.S. Asian and Latin American countries represent the fastest growing markets due to growing number of cancer and diabetes incidences, and improving patent compliance. Furthermore, stringent regulatory policies for approval of medical devices, and high competition in mature countries will compel the companies to focus on the emerging markets in Latin America and Asia.
Scope of the Report
This research report categorizes the global injectable drug delivery technologies marketinto two segments, namely, global injectable drug delivery devices technologies and global injectable drug delivery formulations technologies. These markets are broken down into segments and sub-segments, providing value analysis for 2010, 2011, and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World) to provide in-depth information on the global scenario.
Global Injectable Drug Delivery Technologies Market, By Segment
- Injectable Drug Delivery Devices Technologies
- Injectable Drug Delivery Formulations Technologies
- Conventional Injection Devices
- By Material
- Glass
- Plastics
- By Product
- Fillable Syringes
- Prefilled Syringes
- By Usability
- Reusable
- Disposable
- Self-Injection Devices
- Needle Free Injectors
- By Product
- Fillable Syringes
- Prefilled Syringes
- By Technology
- Jet Based Needle Free Injectors
- Spring Based Needle Free Injectors
- Laser Powered Needle Free Injectors
- Others
- By Usability
- Reusable
- Disposable
- Auto Injectors
- By Products
- Fillable Syringes
- Prefilled Syringes
- By Technology
- Manual Injection Auto Injectors
- Automated Injection Auto Injectors
- By Design
- Standardized Auto Injectors
- Customized Auto Injectors
- By Usability
- Reusable
- Disposable
- Pen Injectors
- By Products
- Single Chambered Pen Injectors
- Dual Chambered Pen Injectors
- By design
- Standardized pen injectors
- Customized pen injectors
- By usability
- Reusable
- Disposable
- Others
- Conventional Drug Delivery Formulations
- Solution
- Reconstituted / Lyophilized Formulations
- Novel Drug Delivery Formulations
- Liposomal Systems
- Microspheres
- Nanoparticles
- Polymeric Micelles
- Others
- Auto Immune Diseases
- Multiple Sclerosis
- Rheumatoid Arthritis
- Crohn's Diseases
- Psoriasis
- Others
- Hormonal Disorders
- Diabetes
- Antithrombotic / Thrombolytic Therapy
- Reproductive Health Diseases
- Anemia
- Osteoporosis
- Others
- Orphan Diseases
- Oncology
- Others
- Pain Management
- Allergies
- Hepatitis C
- Aesthetic Treatment
- North America
- Europe
- Asia-Pacific
- RoW
1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
1.5.5 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.3.1 DRIVERS
3.3.1.1 Technological Advancements
3.3.1.2 Product Life Cycle Management
3.3.1.3 Surge of Biologics in Pharmaceutical Markets
3.3.1.4 Rising Incidences of Cancer and Diabetes
3.3.1.5 Improving Patient Compliance
3.3.2 RESTRAINTS
3.3.2.1 Regulatory Hurdles
3.3.2.2 Needle-stick Injuries and Infections
3.3.2.3 Development of Alternate Delivery Methods
3.3.2.4 Product Recalls
3.3.3 OPPORTUNITIES
3.3.3.1 Emerging Markets (India, China, Brazil, Mexico and Latin America)
3.3.3.2 Development of Biosimilars in the Pharmaceutical Market
3.3.4 CHALLENGES
3.3.4.1 Sustainability of Players in Highly Competitive Market
3.4 MARKET SHARE ANALYSIS, BY MAJOR PLAYERS
3.4.1 CONVENTIONAL INJECTABLE DEVICES
3.4.2 SELF-INJECTION DEVICES
3.4.2.1 Needle Free Injectors
3.4.2.2 Auto Injectors
3.4.2.3 Pen Injectors
4 GLOBAL INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET
4.1 INTRODUCTION
4.2 MARKET SEGMENTATION
4.3 MANUFACTURERS CRITERIA FOR SELECTION OF AN INJECTABLE DEVICE
4.4 CONVENTIONAL INJECTABLE DRUG DELVERY DEVICES
4.4.1 BY USABILITY
4.4.1.1 Disposable
4.4.1.2 Reusable
4.4.2 BY MATERIAL
4.4.2.1 Glass
4.4.2.2 Plastic
4.4.3 BY PRODUCT
4.4.3.1 Prefilled
4.4.3.2 Fillable
4.5 SELF-INJECTION DEVICES
4.5.1 MARKET SEGMENTATION
4.5.2 SELECTION CRITERIA FOR SELF-INJECTION DEVICE
4.5.3 PEN INJECTORS
4.5.3.1 By Product
4.5.3.1.1 Single chamber pen injectors
4.5.3.1.2 Dual chamber pen injectors
4.5.3.2 By Usability
4.5.3.2.1 Disposable pen injectors
4.5.3.2.2 Reusable pen injectors
4.5.3.3 By Design
4.5.3.3.1 Standard pen injectors
4.5.3.3.2 Customized pen injectors
4.5.4 NEEDLE-FREE INJECTORS
4.5.4.1 By Product
4.5.4.1.1 Prefilled needle free injectors
4.5.4.1.2 Fillable needle free injectors
4.5.4.2 By Technology
4.5.4.2.1 Jet-based needle-free injectors
4.5.4.2.2 Spring-based needle-Free injectors
4.5.4.2.3 Laser-based needle free injectors
4.5.4.2.4 Vibration-based needle free injectors
4.5.4.3 By Usability
4.5.4.3.1 Disposable
4.5.4.3.2 Reusable
4.5.5 AUTO INJECTORS
4.5.5.1 By Product
4.5.5.1.1 Prefilled auto injectors
4.5.5.1.2 Fillable auto injectors
4.5.5.2 By Technology
4.5.5.2.1 Automated auto injectors
4.5.5.2.2 Manual auto injectors
4.5.5.3 By Design
4.5.5.3.1 Standardized auto injectors
4.5.5.3.2 Customized auto injectors
4.5.5.4 By Usability
4.5.5.4.1 Disposable auto injectors
4.5.5.4.2 Reusable auto injectors
4.6 OTHERS
5 GLOBAL INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET
5.1 INTRODUCTION
5.2 CONVENTIONAL DRUG DELIVERY
5.2.1 INJECTABLE SOLUTIONS
5.2.2 RECONSTITUTED/LYOPHILIZED FORMULATIONS
5.3 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES
5.3.1 MARKET SEGMENTATION
5.3.2 LIPOSOMAL SYSTEMS
5.3.3 MICROSPHERES
5.3.4 NANOPARTICLES
5.3.5 POLYMERIC MICELLES
5.3.6 OTHERS
6 GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS
6.1 INTRODUCTION
6.2 AUTO-IMMUNE DISEASES
6.2.1 MULTIPLE SCLEROSIS
6.2.2 RHEUMATOID ARTHRITIS
6.2.3 CROHN'S DISEASES
6.2.4 PSORIASIS
6.2.5 OTHERS
6.3 HORMONAL DISORDERS
6.3.1 DIABETES
6.3.2 ANEMIA
6.3.3 REPRODUCTIVE HEALTH DISEASES
6.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
6.3.5 OSTEOPOROSIS
6.3.6 GROWTH HORMONE DEFICIENCY
6.4 ORPHAN/RARE DISEASES
6.5 ONCOLOGY
6.6 OTHERS
6.6.1 PAIN MANAGEMENT
6.6.2 HEPATITIS C
6.6.3 ALLERGIES
6.6.4 AESTHETIC TREATMENT
7 GEOGRAPHIC ANALYSIS
7.1 INTRODUCTION
7.1.1 NORTH AMERICA DOMINATES THE MARKET
7.2 NORTH AMERICA
7.2.1 GROWING INCIDENCES OF DIABETES AND DEVELOPMENTS IN NEEDLE FREE TECHNOLOGY DRIVE THE MARKET
7.2.2 NEEDLESTICK INJURIES HAVE BEEN HINDERING THIS MARKET
7.3 EUROPE
7.3.1 LIBERALIZATION OF GENERICS MARKET AND SURGE IN BIOLOGIC HAS BEEN DRIVING THE MARKET
7.3.2 HIGH PRESENCE OF INJECTABLE DRUG DELIVERY MARKET LEADERS DRIVES THE MARKET
7.3.3 HORMONAL DISORDERS HAVE BEEN HIGHLY AFFECTING THE DEMOGRAPHICS IN EUROPE
7.3.4 THE REGION HAS STRICT LEGISLATIONS TO PREVENT RISING INCIDENCES OF NEEDLESTICK INJURIES
7.4 ASIA-PACIFIC
7.4.1 APAC IS THE FASTEST GROWING REGION FOR THIS MARKET
7.4.2 THE REGION EXPERIENCES RISING FOCUS OF VARIOUS GIANT PLAYERS
7.5 ROW
7.5.1 RISING INCIDENCES OF CANCER AND DIABETES AS WELL AS ADAPTIVE REGULATORY POLICIES IS DRIVING THE MARKET
7.5.2 ADAPTIVE REGULATORY POLICIES IN MEXICO & BRAZIL IS SUPPORTING THE MARKET GROWTH
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
8.2 EXPANSION
8.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
8.4 NEW PRODUCT LAUNCH
8.5 MERGERS & ACQUISITIONS
8.6 OTHER DEVELOPMENTS
8.7 APPROVALS
9 COMPANY PROFILES (OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, & DEVELOPMENTS)
9.1 ALKERMES, INC.
9.2 ANTARES PHARMA, INC.
9.3 BAXTER INTERNATIONAL, INC.
9.4 BECTON, DICKINSON AND COMPANY
9.5 BESPAK EUROPE, LTD. (SUBSIDIARY OF CONSORT MEDICAL, PLC)
9.6 CROSSJECT
9.7 ELCAM MEDICAL
9.8 ELI LILLY AND COMPANY
9.9 GERRESHEIMER AG
9.10 HASELMEIER GMBH
9.11 INJEX PHARMA GMBH (SUBSIDIARY OF HNS INTERNATIONAL, INC.)
9.12 NOVO NORDISK A/S
9.13 OWEN MUMFORD, LTD.
9.14 SANOFI
9.15 SCHOTT AG
9.16 SHL GROUP
9.17 TERUMO CORPORATION
9.18 UNILIFE CORPORATION
9.19 VETTER PHARMA-FERTIGUNG GMBH & CO. KG
9.20 WEST PHARMACEUTICAL SERVICES, INC.
9.21 YPSOMED HOLDING AG
9.22 ZOGENIX, INC. (Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.)
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
1.5.5 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.3.1 DRIVERS
3.3.1.1 Technological Advancements
3.3.1.2 Product Life Cycle Management
3.3.1.3 Surge of Biologics in Pharmaceutical Markets
3.3.1.4 Rising Incidences of Cancer and Diabetes
3.3.1.5 Improving Patient Compliance
3.3.2 RESTRAINTS
3.3.2.1 Regulatory Hurdles
3.3.2.2 Needle-stick Injuries and Infections
3.3.2.3 Development of Alternate Delivery Methods
3.3.2.4 Product Recalls
3.3.3 OPPORTUNITIES
3.3.3.1 Emerging Markets (India, China, Brazil, Mexico and Latin America)
3.3.3.2 Development of Biosimilars in the Pharmaceutical Market
3.3.4 CHALLENGES
3.3.4.1 Sustainability of Players in Highly Competitive Market
3.4 MARKET SHARE ANALYSIS, BY MAJOR PLAYERS
3.4.1 CONVENTIONAL INJECTABLE DEVICES
3.4.2 SELF-INJECTION DEVICES
3.4.2.1 Needle Free Injectors
3.4.2.2 Auto Injectors
3.4.2.3 Pen Injectors
4 GLOBAL INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET
4.1 INTRODUCTION
4.2 MARKET SEGMENTATION
4.3 MANUFACTURERS CRITERIA FOR SELECTION OF AN INJECTABLE DEVICE
4.4 CONVENTIONAL INJECTABLE DRUG DELVERY DEVICES
4.4.1 BY USABILITY
4.4.1.1 Disposable
4.4.1.2 Reusable
4.4.2 BY MATERIAL
4.4.2.1 Glass
4.4.2.2 Plastic
4.4.3 BY PRODUCT
4.4.3.1 Prefilled
4.4.3.2 Fillable
4.5 SELF-INJECTION DEVICES
4.5.1 MARKET SEGMENTATION
4.5.2 SELECTION CRITERIA FOR SELF-INJECTION DEVICE
4.5.3 PEN INJECTORS
4.5.3.1 By Product
4.5.3.1.1 Single chamber pen injectors
4.5.3.1.2 Dual chamber pen injectors
4.5.3.2 By Usability
4.5.3.2.1 Disposable pen injectors
4.5.3.2.2 Reusable pen injectors
4.5.3.3 By Design
4.5.3.3.1 Standard pen injectors
4.5.3.3.2 Customized pen injectors
4.5.4 NEEDLE-FREE INJECTORS
4.5.4.1 By Product
4.5.4.1.1 Prefilled needle free injectors
4.5.4.1.2 Fillable needle free injectors
4.5.4.2 By Technology
4.5.4.2.1 Jet-based needle-free injectors
4.5.4.2.2 Spring-based needle-Free injectors
4.5.4.2.3 Laser-based needle free injectors
4.5.4.2.4 Vibration-based needle free injectors
4.5.4.3 By Usability
4.5.4.3.1 Disposable
4.5.4.3.2 Reusable
4.5.5 AUTO INJECTORS
4.5.5.1 By Product
4.5.5.1.1 Prefilled auto injectors
4.5.5.1.2 Fillable auto injectors
4.5.5.2 By Technology
4.5.5.2.1 Automated auto injectors
4.5.5.2.2 Manual auto injectors
4.5.5.3 By Design
4.5.5.3.1 Standardized auto injectors
4.5.5.3.2 Customized auto injectors
4.5.5.4 By Usability
4.5.5.4.1 Disposable auto injectors
4.5.5.4.2 Reusable auto injectors
4.6 OTHERS
5 GLOBAL INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET
5.1 INTRODUCTION
5.2 CONVENTIONAL DRUG DELIVERY
5.2.1 INJECTABLE SOLUTIONS
5.2.2 RECONSTITUTED/LYOPHILIZED FORMULATIONS
5.3 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES
5.3.1 MARKET SEGMENTATION
5.3.2 LIPOSOMAL SYSTEMS
5.3.3 MICROSPHERES
5.3.4 NANOPARTICLES
5.3.5 POLYMERIC MICELLES
5.3.6 OTHERS
6 GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS
6.1 INTRODUCTION
6.2 AUTO-IMMUNE DISEASES
6.2.1 MULTIPLE SCLEROSIS
6.2.2 RHEUMATOID ARTHRITIS
6.2.3 CROHN'S DISEASES
6.2.4 PSORIASIS
6.2.5 OTHERS
6.3 HORMONAL DISORDERS
6.3.1 DIABETES
6.3.2 ANEMIA
6.3.3 REPRODUCTIVE HEALTH DISEASES
6.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
6.3.5 OSTEOPOROSIS
6.3.6 GROWTH HORMONE DEFICIENCY
6.4 ORPHAN/RARE DISEASES
6.5 ONCOLOGY
6.6 OTHERS
6.6.1 PAIN MANAGEMENT
6.6.2 HEPATITIS C
6.6.3 ALLERGIES
6.6.4 AESTHETIC TREATMENT
7 GEOGRAPHIC ANALYSIS
7.1 INTRODUCTION
7.1.1 NORTH AMERICA DOMINATES THE MARKET
7.2 NORTH AMERICA
7.2.1 GROWING INCIDENCES OF DIABETES AND DEVELOPMENTS IN NEEDLE FREE TECHNOLOGY DRIVE THE MARKET
7.2.2 NEEDLESTICK INJURIES HAVE BEEN HINDERING THIS MARKET
7.3 EUROPE
7.3.1 LIBERALIZATION OF GENERICS MARKET AND SURGE IN BIOLOGIC HAS BEEN DRIVING THE MARKET
7.3.2 HIGH PRESENCE OF INJECTABLE DRUG DELIVERY MARKET LEADERS DRIVES THE MARKET
7.3.3 HORMONAL DISORDERS HAVE BEEN HIGHLY AFFECTING THE DEMOGRAPHICS IN EUROPE
7.3.4 THE REGION HAS STRICT LEGISLATIONS TO PREVENT RISING INCIDENCES OF NEEDLESTICK INJURIES
7.4 ASIA-PACIFIC
7.4.1 APAC IS THE FASTEST GROWING REGION FOR THIS MARKET
7.4.2 THE REGION EXPERIENCES RISING FOCUS OF VARIOUS GIANT PLAYERS
7.5 ROW
7.5.1 RISING INCIDENCES OF CANCER AND DIABETES AS WELL AS ADAPTIVE REGULATORY POLICIES IS DRIVING THE MARKET
7.5.2 ADAPTIVE REGULATORY POLICIES IN MEXICO & BRAZIL IS SUPPORTING THE MARKET GROWTH
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
8.2 EXPANSION
8.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
8.4 NEW PRODUCT LAUNCH
8.5 MERGERS & ACQUISITIONS
8.6 OTHER DEVELOPMENTS
8.7 APPROVALS
9 COMPANY PROFILES (OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, & DEVELOPMENTS)
9.1 ALKERMES, INC.
9.2 ANTARES PHARMA, INC.
9.3 BAXTER INTERNATIONAL, INC.
9.4 BECTON, DICKINSON AND COMPANY
9.5 BESPAK EUROPE, LTD. (SUBSIDIARY OF CONSORT MEDICAL, PLC)
9.6 CROSSJECT
9.7 ELCAM MEDICAL
9.8 ELI LILLY AND COMPANY
9.9 GERRESHEIMER AG
9.10 HASELMEIER GMBH
9.11 INJEX PHARMA GMBH (SUBSIDIARY OF HNS INTERNATIONAL, INC.)
9.12 NOVO NORDISK A/S
9.13 OWEN MUMFORD, LTD.
9.14 SANOFI
9.15 SCHOTT AG
9.16 SHL GROUP
9.17 TERUMO CORPORATION
9.18 UNILIFE CORPORATION
9.19 VETTER PHARMA-FERTIGUNG GMBH & CO. KG
9.20 WEST PHARMACEUTICAL SERVICES, INC.
9.21 YPSOMED HOLDING AG
9.22 ZOGENIX, INC. (Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.)
LIST OF TABLES
TABLE 1 GLOBAL INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 2 GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 3 INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 4 GLOBAL INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017 ($BILLION)
TABLE 5 INJECTION DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 6 CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 7 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2010 – 2017 ($BILLION)
TABLE 8 DISPOSABLE CONVENTIONAL DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 9 REUSABLE CONVENTIONAL DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 10 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2010 – 2017 ($BILLION)
TABLE 11 CONVENTIONAL INJECTION DEVICES (GLASS) MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 12 CONVENTIONAL INJECTION DEVICES (PLASTIC) MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 13 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($BILLION)
TABLE 14 PREFILLED CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 15 FILLABLE CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 16 MAJOR THERAPEUTIC AREAS FOR SELF-INJECTION DEVICES
TABLE 17 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($BILLION)
TABLE 18 SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 19 PEN INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 20 GLOBAL PEN INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 21 SINGLE CHAMBER PEN INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 22 DUAL CHAMBER PEN INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 23 GLOBAL PEN INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 24 DISPOSABLE PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 25 REUSABLE PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 26 GLOBAL PEN INJECTORS MARKET, BY DESIGN, 2010 – 2017 ($MILLION)
TABLE 27 STANDARD PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 28 CUSTOMIZED PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 29 NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 30 GLOBAL NEEDLE FREE INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 31 PREFILLED NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 32 FILLABLE NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 33 GLOBAL NEEDLE FREE INJECTORS MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 34 JET-BASED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 35 SPRING-BASED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 36 LASER-POWERED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 37 VIBRATION-BASED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 38 GLOBAL NEEDLE FREE INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 39 DISPOSABLE NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 40 REUSABLE NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 41 AUTO INJECTORS PRODUCTS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 42 GLOBAL AUTO INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 43 PREFILLED AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 44 FILLABLE AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 45 GLOBAL AUTO INJECTORS MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 46 AUTOMATED AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 47 MANUAL AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 48 GLOBAL AUTO INJECTORS MARKET, BY DESIGN, 2010 – 2017 ($MILLION)
TABLE 49 STANDARDIZED AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 50 CUSTOMIZED AUTO INJECTORS AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 51 GLOBAL AUTO INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 52 DISPOSABLE AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 53 REUSABLE AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 54 OTHERS INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 55 GLOBAL INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 56 INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 57 GLOBAL CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($BILLION)
TABLE 58 CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 59 INJECTABLE SOLUTIONS CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 60 RECONSTITUTED/LYOPHILIZED CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 61 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($BILLION)
TABLE 62 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 63 LIPOSOME DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 64 MICROSPHERES DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 65 NANOPARTICLES DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 66 POLYMERIC MICELLES DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 67 OTHERS NOVEL DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 68 GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 69 GLOBAL AUTO-IMMUNE THERAPEUTIC MARKET, BY INDICATION, 2010 – 2017 ($MILLION)
TABLE 70 AUTO-IMMUNE THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 71 MULTIPLE SCLEROSIS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 72 RHEUMATOID ARTHRITIS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 73 CROHN'S DISEASES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 74 PSORIASIS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 75 OTHER AUTO-IMMUNE DISEASES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 76 GLOBAL HORMONAL DISORDERS, BY INDICATION, 2010 – 2017 ($MILLION)
TABLE 77 HORMONAL DISORDERS MARKET, BY GEOGRAPHY, 2010 – 2017($BILLION)
TABLE 78 DIABETES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 79 ANEMIA MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 80 REPRODUCTIVE HEALTH DISEASES MARKET, BY GEOGRAPHY, 2010 – 2017($MILLION)
TABLE 81 ANTITHROMBOTIC THERAPY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 82 OSTEOPOROSIS MARKET, BY GEOGRAPHY, 2010 – 2017($MILLION)
TABLE 83 GROWTH HORMONE DEFICIENCY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 84 ORPHAN/RARE DISEASES THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 85 ONCOLOGY THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 86 GLOBAL OTHER THERAPEUTIC MARKET, 2010 – 2017 ($MILLION)
TABLE 87 OTHER THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 88 PAIN MANAGEMENT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 89 HEPATITIS C MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 90 ALLERGIES/ANAPHYLYTIC SHOCK MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 91 AESTHETIC TREATMENT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 92 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET,2010 – 2017 ($BILLION)
TABLE 93 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 94 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($BILLION)
TABLE 95 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION 2010 – 2017 ($BILLION)
TABLE 96 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, 2010 – 2017 ($BILLION)
TABLE 97 EUROPE: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, 2010 – 2017 ($MILLION)
TABLE 98 EUROPE INJECTABLE DRUG DELIVERY FORMULATIONS TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 99 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICTION, 2010 – 2017 ($BILLION)
TABLE 100 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT,2010 – 2017 ($BILLION)
TABLE 101 APAC: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 102 APAC: INJECTABLE DRUG DELIVERY FORMULATIONS TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 103 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($MILLION)
TABLE 104 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 105 ROW: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 106 ROW: INJECTABLE DRUG DELIVERY FORMULATIONS TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 107 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($MILLION)
TABLE 108 EXPANSION, 2010 – 2013
TABLE 109 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013
TABLE 110 NEW PRODUCT LAUNCH, 2010 – 2013
TABLE 111 MERGERS & ACQUISITIONS, 2010 – 2013
TABLE 112 OTHER DEVELOPMENTS, 2010 – 2013
TABLE 113 APPROVALS, 2010 – 2013
TABLE 114 ALKERMES: TOTAL REVENUE AND R&D EXPENSES, 2009– 2011 ($MILLION)
TABLE 115 ALKERMES: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 116 ANTARES PHARMA: TOTAL REVENUES AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 117 ANTARES PHARMA: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 118 ANTARES PHARMA: TOTAL REVENUE, BY PRODUCT, 2010 – 2012 ($MILLION)
TABLE 119 BAXTER INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 120 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 121 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE, 2010 – 2012($MILLION)
TABLE 122 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 123 BECTON DICKINSON: TOTAL REVENUES & R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 124 BECTON DICKINSON: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 125 BECTON DICKINSON: MEDICAL DIVISION TOTAL REVENUE, 2010 – 2012 ($MILLION)
TABLE 126 BECTON DICKINSON: TOTAL REVENUE, BY GEOGRAPHY, 2010– 2012 ($MILLION)
TABLE 127 CONSORT MEDICAL: TOTAL REVENUE AND R&D EXPENSE, 2009 – 2011 ($MILLION)
TABLE 128 CONSORT MEDICAL: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 129 ELI LILLY & CO: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION)
TABLE 130 ELI LILLY & CO: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($BILLION)
TABLE 131 ELI LILLY & CO: TOTAL REVENUE BY GEOGRAPHY, 2010 – 2012 ($BILLION)
TABLE 132 GERRESHEIMER AG: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 133 GERRESHEIMER AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 134 GERRESHEIMER AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 135 NOVO NORDISK: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION)
TABLE 136 NOVO NORDISK: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($BILLION)
TABLE 137 NOVO NORDISK: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($BILLION)
TABLE 138 SANOFI: TOTAL REVENUE & R&D EXPENDITURE, 2010 – 2012 ($BILLION)
TABLE 139 SANOFI: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($BILLION)
TABLE 140 SANOFI: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($BILLION)
TABLE 141 SCHOTT AG: TOTAL REVENUE AND R&D EXPENDITURES, 2010 – 2012 ($MILLION)
TABLE 142 SCHOTT AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 143 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 144 TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 145 TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 146 UNILIFE CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 147 UNILIFE CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 148 WEST PHARMA: TOTAL REVENUES AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 149 WEST PHARMA: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 150 WEST PHARMA: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2012 ($MILLION)
TABLE 151 YPSOMED: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 152 YPSOMED: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 153 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2009 ($MILLION)
TABLE 154 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2011 ($MILLION)
TABLE 155 ZOGENIX, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 1 GLOBAL INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 2 GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 3 INJECTION DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 4 GLOBAL INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY PRODUCT, 2010 – 2017 ($BILLION)
TABLE 5 INJECTION DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 6 CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 7 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2010 – 2017 ($BILLION)
TABLE 8 DISPOSABLE CONVENTIONAL DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 9 REUSABLE CONVENTIONAL DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 10 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2010 – 2017 ($BILLION)
TABLE 11 CONVENTIONAL INJECTION DEVICES (GLASS) MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 12 CONVENTIONAL INJECTION DEVICES (PLASTIC) MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 13 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($BILLION)
TABLE 14 PREFILLED CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 15 FILLABLE CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 16 MAJOR THERAPEUTIC AREAS FOR SELF-INJECTION DEVICES
TABLE 17 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($BILLION)
TABLE 18 SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 19 PEN INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 20 GLOBAL PEN INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 21 SINGLE CHAMBER PEN INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 22 DUAL CHAMBER PEN INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 23 GLOBAL PEN INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 24 DISPOSABLE PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 25 REUSABLE PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 26 GLOBAL PEN INJECTORS MARKET, BY DESIGN, 2010 – 2017 ($MILLION)
TABLE 27 STANDARD PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 28 CUSTOMIZED PEN INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 29 NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 30 GLOBAL NEEDLE FREE INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 31 PREFILLED NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 32 FILLABLE NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 33 GLOBAL NEEDLE FREE INJECTORS MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 34 JET-BASED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 35 SPRING-BASED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 36 LASER-POWERED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 37 VIBRATION-BASED NEEDLE FREE INJECTOR MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 38 GLOBAL NEEDLE FREE INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 39 DISPOSABLE NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 40 REUSABLE NEEDLE FREE INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 41 AUTO INJECTORS PRODUCTS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 42 GLOBAL AUTO INJECTORS MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 43 PREFILLED AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 44 FILLABLE AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 45 GLOBAL AUTO INJECTORS MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 46 AUTOMATED AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 47 MANUAL AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 48 GLOBAL AUTO INJECTORS MARKET, BY DESIGN, 2010 – 2017 ($MILLION)
TABLE 49 STANDARDIZED AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 50 CUSTOMIZED AUTO INJECTORS AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 51 GLOBAL AUTO INJECTORS MARKET, BY USABILITY, 2010 – 2017 ($MILLION)
TABLE 52 DISPOSABLE AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 53 REUSABLE AUTO INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 54 OTHERS INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 55 GLOBAL INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 56 INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 57 GLOBAL CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($BILLION)
TABLE 58 CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 59 INJECTABLE SOLUTIONS CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 60 RECONSTITUTED/LYOPHILIZED CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 61 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($BILLION)
TABLE 62 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 63 LIPOSOME DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 64 MICROSPHERES DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 65 NANOPARTICLES DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 66 POLYMERIC MICELLES DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 67 OTHERS NOVEL DRUG DELIVEY FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 68 GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 69 GLOBAL AUTO-IMMUNE THERAPEUTIC MARKET, BY INDICATION, 2010 – 2017 ($MILLION)
TABLE 70 AUTO-IMMUNE THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 71 MULTIPLE SCLEROSIS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 72 RHEUMATOID ARTHRITIS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 73 CROHN'S DISEASES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 74 PSORIASIS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 75 OTHER AUTO-IMMUNE DISEASES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 76 GLOBAL HORMONAL DISORDERS, BY INDICATION, 2010 – 2017 ($MILLION)
TABLE 77 HORMONAL DISORDERS MARKET, BY GEOGRAPHY, 2010 – 2017($BILLION)
TABLE 78 DIABETES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 79 ANEMIA MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 80 REPRODUCTIVE HEALTH DISEASES MARKET, BY GEOGRAPHY, 2010 – 2017($MILLION)
TABLE 81 ANTITHROMBOTIC THERAPY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 82 OSTEOPOROSIS MARKET, BY GEOGRAPHY, 2010 – 2017($MILLION)
TABLE 83 GROWTH HORMONE DEFICIENCY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 84 ORPHAN/RARE DISEASES THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 85 ONCOLOGY THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 86 GLOBAL OTHER THERAPEUTIC MARKET, 2010 – 2017 ($MILLION)
TABLE 87 OTHER THERAPEUTIC MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 88 PAIN MANAGEMENT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 89 HEPATITIS C MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 90 ALLERGIES/ANAPHYLYTIC SHOCK MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 91 AESTHETIC TREATMENT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 92 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET,2010 – 2017 ($BILLION)
TABLE 93 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 94 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET, 2010 – 2017 ($BILLION)
TABLE 95 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION 2010 – 2017 ($BILLION)
TABLE 96 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, 2010 – 2017 ($BILLION)
TABLE 97 EUROPE: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, 2010 – 2017 ($MILLION)
TABLE 98 EUROPE INJECTABLE DRUG DELIVERY FORMULATIONS TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 99 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICTION, 2010 – 2017 ($BILLION)
TABLE 100 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT,2010 – 2017 ($BILLION)
TABLE 101 APAC: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 102 APAC: INJECTABLE DRUG DELIVERY FORMULATIONS TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($BILLION)
TABLE 103 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($MILLION)
TABLE 104 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 105 ROW: INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 106 ROW: INJECTABLE DRUG DELIVERY FORMULATIONS TECHNOLOGIES MARKET, BY SEGMENT, 2010 – 2017 ($MILLION)
TABLE 107 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($MILLION)
TABLE 108 EXPANSION, 2010 – 2013
TABLE 109 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013
TABLE 110 NEW PRODUCT LAUNCH, 2010 – 2013
TABLE 111 MERGERS & ACQUISITIONS, 2010 – 2013
TABLE 112 OTHER DEVELOPMENTS, 2010 – 2013
TABLE 113 APPROVALS, 2010 – 2013
TABLE 114 ALKERMES: TOTAL REVENUE AND R&D EXPENSES, 2009– 2011 ($MILLION)
TABLE 115 ALKERMES: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 116 ANTARES PHARMA: TOTAL REVENUES AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 117 ANTARES PHARMA: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 118 ANTARES PHARMA: TOTAL REVENUE, BY PRODUCT, 2010 – 2012 ($MILLION)
TABLE 119 BAXTER INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 120 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 121 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE, 2010 – 2012($MILLION)
TABLE 122 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 123 BECTON DICKINSON: TOTAL REVENUES & R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 124 BECTON DICKINSON: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 125 BECTON DICKINSON: MEDICAL DIVISION TOTAL REVENUE, 2010 – 2012 ($MILLION)
TABLE 126 BECTON DICKINSON: TOTAL REVENUE, BY GEOGRAPHY, 2010– 2012 ($MILLION)
TABLE 127 CONSORT MEDICAL: TOTAL REVENUE AND R&D EXPENSE, 2009 – 2011 ($MILLION)
TABLE 128 CONSORT MEDICAL: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 129 ELI LILLY & CO: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION)
TABLE 130 ELI LILLY & CO: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($BILLION)
TABLE 131 ELI LILLY & CO: TOTAL REVENUE BY GEOGRAPHY, 2010 – 2012 ($BILLION)
TABLE 132 GERRESHEIMER AG: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 133 GERRESHEIMER AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 134 GERRESHEIMER AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 135 NOVO NORDISK: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION)
TABLE 136 NOVO NORDISK: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($BILLION)
TABLE 137 NOVO NORDISK: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($BILLION)
TABLE 138 SANOFI: TOTAL REVENUE & R&D EXPENDITURE, 2010 – 2012 ($BILLION)
TABLE 139 SANOFI: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($BILLION)
TABLE 140 SANOFI: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($BILLION)
TABLE 141 SCHOTT AG: TOTAL REVENUE AND R&D EXPENDITURES, 2010 – 2012 ($MILLION)
TABLE 142 SCHOTT AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 143 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 144 TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 145 TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 146 UNILIFE CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
TABLE 147 UNILIFE CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 148 WEST PHARMA: TOTAL REVENUES AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 149 WEST PHARMA: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 150 WEST PHARMA: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2012 ($MILLION)
TABLE 151 YPSOMED: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 152 YPSOMED: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 153 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2009 ($MILLION)
TABLE 154 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2011 ($MILLION)
TABLE 155 ZOGENIX, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2012 & 2017
FIGURE 2 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012
FIGURE 3 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION
FIGURE 4 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION
FIGURE 5 MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATION
FIGURE 6 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET DYNAMICS
FIGURE 7 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY KEY PLAYERS, 2012 ($MILLION)
FIGURE 8 GLOBAL SELF-INJECTION DEVICES MARKET, BY KEY PLAYERS, 2012 ($MILLION)
FIGURE 9 GLOBAL NEEDLE FREE INJECTOR MARKET, BY KEY PLAYERS, 2012 ($MILLION)
FIGURE 10 GLOBAL AUTO INJECTOR MARKET, BY KEY PLAYERS, 2012 ($MILLION)
FIGURE 11 GLOBAL PEN INJECTOR MARKET, BY KEY PLAYERS, 2012 ($MILLION)
FIGURE 12 INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET SEGMENTATION
FIGURE 13 FACTORS AFFECTING SELECTION OF AN INJECTABLE DEVICE
FIGURE 14 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($BILLION)
FIGURE 15 SELF-INJECTION DEVICES MARKET SEGMENTATION
FIGURE 16 FACTORS AFFECTING SELECTION OF SELF-INJECTION DEVICE
FIGURE 17 CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET SEGMENTATION
FIGURE 18 GLOBAL NOVEL DRUG DELIVEY FORMULATION MARKET, 2012 & 2017 ($BILLION)
FIGURE 19 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES SEGMENTATION
FIGURE 20 GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($BILLION)
FIGURE 21 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY THERAPEUTIC APPLICATIONS
FIGURE 22 AUTO-IMMUNE THERAPEUTIC MARKET SEGMENTATION
FIGURE 23 HORMONAL DISORDERS MARKET SEGMENTATION
FIGURE 24 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012 – 2017 ($BILLION)
FIGURE 25 KEY GROWTH STRATEGIES, 2010 – 2013
FIGURE 26 KEY PLAYERS FOCUSING ON EXPANSION, 2010 – 2013
FIGURE 27 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES, 2010 – 2013
FIGURE 1 GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT, 2012 & 2017
FIGURE 2 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012
FIGURE 3 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION
FIGURE 4 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION
FIGURE 5 MARKET SEGMENTATION OF INJECTABLE DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATION
FIGURE 6 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET DYNAMICS
FIGURE 7 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY KEY PLAYERS, 2012 ($MILLION)
FIGURE 8 GLOBAL SELF-INJECTION DEVICES MARKET, BY KEY PLAYERS, 2012 ($MILLION)
FIGURE 9 GLOBAL NEEDLE FREE INJECTOR MARKET, BY KEY PLAYERS, 2012 ($MILLION)
FIGURE 10 GLOBAL AUTO INJECTOR MARKET, BY KEY PLAYERS, 2012 ($MILLION)
FIGURE 11 GLOBAL PEN INJECTOR MARKET, BY KEY PLAYERS, 2012 ($MILLION)
FIGURE 12 INJECTABLE DRUG DELIVERY DEVICES TECHNOLOGIES MARKET SEGMENTATION
FIGURE 13 FACTORS AFFECTING SELECTION OF AN INJECTABLE DEVICE
FIGURE 14 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($BILLION)
FIGURE 15 SELF-INJECTION DEVICES MARKET SEGMENTATION
FIGURE 16 FACTORS AFFECTING SELECTION OF SELF-INJECTION DEVICE
FIGURE 17 CONVENTIONAL DRUG DELIVERY FORMULATION TECHNOLOGIES MARKET SEGMENTATION
FIGURE 18 GLOBAL NOVEL DRUG DELIVEY FORMULATION MARKET, 2012 & 2017 ($BILLION)
FIGURE 19 NOVEL DRUG DELIVERY FORMULATION TECHNOLOGIES SEGMENTATION
FIGURE 20 GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATION, 2010 – 2017 ($BILLION)
FIGURE 21 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY THERAPEUTIC APPLICATIONS
FIGURE 22 AUTO-IMMUNE THERAPEUTIC MARKET SEGMENTATION
FIGURE 23 HORMONAL DISORDERS MARKET SEGMENTATION
FIGURE 24 INJECTABLE DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2012 – 2017 ($BILLION)
FIGURE 25 KEY GROWTH STRATEGIES, 2010 – 2013
FIGURE 26 KEY PLAYERS FOCUSING ON EXPANSION, 2010 – 2013
FIGURE 27 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES, 2010 – 2013
